Products
Caxmotabart Biosimilar Monoclonal Antibody (HER2) for Research
Cat No.: GMP-Bios-INN-1125
Anti-ERBB2/CD340/HER2 therapeutic antibody (Pre-made Caxmotabart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Caxmotabart (development codes LCB-14/FS-1502) is a monoclonal antibody-drug conjugate targeting HER2 (ERBB2). It is developed by LegoChem Biosciences and Shanghai Fosun Pharmaceutical for breast cancer and other solid tumors. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1125-1mg | 1mg | 3090 |
| GMP-Bios-INN-1125-10mg | 10mg | |
| GMP-Bios-INN-1125-100mg | 100mg | |
| GMP-Bios-INN-1125-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Caxmotabart biosimilar, Whole mAb, Anti-ERBB2/CD340/HER2 Antibody: Anti-HER2/ERBB2/CD340/Receptor tyrosine-protein kinase erbB-2 therapeutic antibody |
| INN Name | Caxmotabart |
| Target | ERBB2/CD340/HER2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA |
| 99% SI Structure | 1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL |
| 95-98% SI Structure | 5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | LegoChem Biosciences;Iksuda Therapeutics;LigaChem Biosciences;Shanghai Fosun Pharmaceutical |
| Conditions Approved | Breast cancer;HER2 positive breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours |
| Conditions Active | na |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
